Knight Therapeutics Inc.
GUD.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -236.11% | 88.13% | 100.84% | 161.52% | 123.95% |
| Total Depreciation and Amortization | 4.64% | 6.88% | -2.61% | 1.27% | 3.76% |
| Total Amortization of Deferred Charges | 6.37% | 2.25% | 2.25% | 2.25% | 2.25% |
| Total Other Non-Cash Items | 1,439.11% | -83.65% | -97.53% | -126.11% | -103.83% |
| Change in Net Operating Assets | 111.19% | -1,026.22% | -1,307.94% | -2,070.03% | 32.82% |
| Cash from Operations | 84.76% | -34.26% | -52.96% | -85.98% | 0.97% |
| Capital Expenditure | 26.08% | 20.79% | 17.21% | -11.87% | -163.38% |
| Sale of Property, Plant, and Equipment | -82.08% | -93.68% | -93.68% | -93.51% | -91.76% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 89.66% | 2,083.28% | 206.87% | 429.12% | -35.97% |
| Cash from Investing | -564.83% | -1,503.38% | -286.87% | 407.25% | -45.95% |
| Total Debt Issued | 3,126.89% | 3,713.86% | 2,736.02% | 0.92% | -27.59% |
| Total Debt Repaid | -334.14% | -178.97% | -167.99% | 9.68% | 5.68% |
| Issuance of Common Stock | -26.55% | -22.36% | 78.39% | 187.85% | 163.68% |
| Repurchase of Common Stock | 28.36% | 62.71% | 63.61% | 71.51% | 83.39% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.28% | 18.73% | 27.04% | 28.39% | 22.82% |
| Cash from Financing | 117.28% | 145.97% | 143.49% | 52.22% | 59.39% |
| Foreign Exchange rate Adjustments | -278.19% | -60.26% | -3,045.88% | -14.13% | -41.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.05% | 286.41% | -33.40% | 579.22% | 267.10% |